Cargando…

Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation

BACKGROUND: Tumour characteristics and orthotopic liver transplantation (OLT) criteria are risks for recurrence of hepatocellular carcinoma (HCC). In Asia, most HCC is caused by chronic hepatitis B infection. Whether hepatitis B virus DNA (HBV DNA) is a risk factor for HCC recurrence after OLT is no...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dali, Feng, Danni, Ren, Minjuan, Bai, Ying, Liu, Zhenwen, Wang, Hongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455325/
https://www.ncbi.nlm.nih.gov/pubmed/35930293
http://dx.doi.org/10.1080/07853890.2022.2107233
_version_ 1784785558003777536
author Zhang, Dali
Feng, Danni
Ren, Minjuan
Bai, Ying
Liu, Zhenwen
Wang, Hongbo
author_facet Zhang, Dali
Feng, Danni
Ren, Minjuan
Bai, Ying
Liu, Zhenwen
Wang, Hongbo
author_sort Zhang, Dali
collection PubMed
description BACKGROUND: Tumour characteristics and orthotopic liver transplantation (OLT) criteria are risks for recurrence of hepatocellular carcinoma (HCC). In Asia, most HCC is caused by chronic hepatitis B infection. Whether hepatitis B virus DNA (HBV DNA) is a risk factor for HCC recurrence after OLT is not clear. PATIENTS AND METHODS: In this retrospective study, we classified patients into groups of detectable and undetectable HBV DNA, non-HCC recurrence, and recurrence and performed analyses on differed characteristics between groups and risk factors for HCC recurrence after OLT. RESULTS: Among patients who underwent OLT for HCC, 117 were secondary to CHB infection. CHB was not a risk, but advanced tumour characteristics were risk factor for HCC recurrence. In patients with CHB-HCC, 24 (20.5%) of 117 patients had HCC recurrence. Compared to patients with HBV DNA undetectable (n = 75), patients with detectable HBV DNA (n = 42) had higher AFP concentration (p < .001), higher proportion of macrovascular invasion (p = .014), greater tumour diameter (p < .001), poorer TNM stage (p = .017), and higher proportion of extended OLT criteria (p = .011) and HCC recurrence (p = .036). Preoperative HBV DNA >2000 IU/mL was an independent risk factor for HCC recurrence (OR = 8.35, 95% CI 1.40, 50.00, p = .020). HBV DNA detectable was not a risk for HCC-related death. CONCLUSION: Individuals with preoperative undetectable HBV DNA had advanced tumour characteristics and a higher proportion of HCC recurrence. Antiviral treatment for HCC should be performed, and HBV DNA undetectable should be obtained before OLT. But for an urgent OLT, preoperative detectable HBV DNA may not affect long-term survival. KEY MESSAGES: Patients with HBV DNA detectable had advanced tumour characteristics, a higher proportion of extended OLT criteria, and HCC-recurrence. HBV DNA >2000 IU/mL was a risk factor for HCC recurrence. HBV DNA detectable was not a risk for HCC related death; extended OLT criteria affected long-term survival.
format Online
Article
Text
id pubmed-9455325
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-94553252022-09-09 Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation Zhang, Dali Feng, Danni Ren, Minjuan Bai, Ying Liu, Zhenwen Wang, Hongbo Ann Med Gastroenterology & Hepatology BACKGROUND: Tumour characteristics and orthotopic liver transplantation (OLT) criteria are risks for recurrence of hepatocellular carcinoma (HCC). In Asia, most HCC is caused by chronic hepatitis B infection. Whether hepatitis B virus DNA (HBV DNA) is a risk factor for HCC recurrence after OLT is not clear. PATIENTS AND METHODS: In this retrospective study, we classified patients into groups of detectable and undetectable HBV DNA, non-HCC recurrence, and recurrence and performed analyses on differed characteristics between groups and risk factors for HCC recurrence after OLT. RESULTS: Among patients who underwent OLT for HCC, 117 were secondary to CHB infection. CHB was not a risk, but advanced tumour characteristics were risk factor for HCC recurrence. In patients with CHB-HCC, 24 (20.5%) of 117 patients had HCC recurrence. Compared to patients with HBV DNA undetectable (n = 75), patients with detectable HBV DNA (n = 42) had higher AFP concentration (p < .001), higher proportion of macrovascular invasion (p = .014), greater tumour diameter (p < .001), poorer TNM stage (p = .017), and higher proportion of extended OLT criteria (p = .011) and HCC recurrence (p = .036). Preoperative HBV DNA >2000 IU/mL was an independent risk factor for HCC recurrence (OR = 8.35, 95% CI 1.40, 50.00, p = .020). HBV DNA detectable was not a risk for HCC-related death. CONCLUSION: Individuals with preoperative undetectable HBV DNA had advanced tumour characteristics and a higher proportion of HCC recurrence. Antiviral treatment for HCC should be performed, and HBV DNA undetectable should be obtained before OLT. But for an urgent OLT, preoperative detectable HBV DNA may not affect long-term survival. KEY MESSAGES: Patients with HBV DNA detectable had advanced tumour characteristics, a higher proportion of extended OLT criteria, and HCC-recurrence. HBV DNA >2000 IU/mL was a risk factor for HCC recurrence. HBV DNA detectable was not a risk for HCC related death; extended OLT criteria affected long-term survival. Taylor & Francis 2022-08-05 /pmc/articles/PMC9455325/ /pubmed/35930293 http://dx.doi.org/10.1080/07853890.2022.2107233 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Gastroenterology & Hepatology
Zhang, Dali
Feng, Danni
Ren, Minjuan
Bai, Ying
Liu, Zhenwen
Wang, Hongbo
Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
title Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
title_full Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
title_fullStr Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
title_full_unstemmed Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
title_short Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
title_sort preoperative serum hepatitis b virus dna was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
topic Gastroenterology & Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455325/
https://www.ncbi.nlm.nih.gov/pubmed/35930293
http://dx.doi.org/10.1080/07853890.2022.2107233
work_keys_str_mv AT zhangdali preoperativeserumhepatitisbvirusdnawasariskfactorforhepatocellularcarcinomarecurrenceafterlivertransplantation
AT fengdanni preoperativeserumhepatitisbvirusdnawasariskfactorforhepatocellularcarcinomarecurrenceafterlivertransplantation
AT renminjuan preoperativeserumhepatitisbvirusdnawasariskfactorforhepatocellularcarcinomarecurrenceafterlivertransplantation
AT baiying preoperativeserumhepatitisbvirusdnawasariskfactorforhepatocellularcarcinomarecurrenceafterlivertransplantation
AT liuzhenwen preoperativeserumhepatitisbvirusdnawasariskfactorforhepatocellularcarcinomarecurrenceafterlivertransplantation
AT wanghongbo preoperativeserumhepatitisbvirusdnawasariskfactorforhepatocellularcarcinomarecurrenceafterlivertransplantation